New oral migraine drug, Amerge

March 1998

Glaxo is introducing their new oral migraine drug, Amerge.

Think of Amerge (naratriptan) as similar to oral Imitrex (sumatriptan)...except Amerge is longer-acting.

This means fewer recurrent headaches with Amerge than with Imitrex. About 40% of patients using Imitrex have recurrent headaches because of its short half-life.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Hear a lot more about homocysteine
Venastat to relieve leg swelling due to varicose veins
Singulair (montelukast) for asthma
Serevent is approved for treating chronic obstructive pulmonary disease (COPD)
Obesity & Weight Loss New obesity drug, Meridia
Cardiology New combination antihypertensive called Teczem
Cardiology Whether patients can still take erythromycin before dental procedures to prevent bacterial endocarditis
Neurology & Pain New oral migraine drug, Amerge
Neurology & Pain Tasmar (tolcapone) for Parkinson's
Women's Health New strength of Prempro
Women's Health Topical testosterone for libido
Gastroenterology PrevPac, a new kit for H. pylori
Diabetes Boxed warning about which patients shouldn't take metformin (Glucophage)
Diabetes Another new drug for type 2 diabetes, called Prandin (repaglinide)
STIs New STD treatment guidelines
Poison Prevention National Poison Prevention Week is this month

New oral migraine drug, Amerge

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents